Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Intratumoral heterogeneity is a critical frontier in understanding how the tumor
microenvironment (TME) propels malignant progression. Here, we deconvolute the human …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in
patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor …

Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease refractory to all
targeted and immune therapies. However, our understanding of PDAC microenvironment …

Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of
pancreatic cancer indicate the cellular processes that are targeted for malignant …

Purpose: To determine the impact of basal-like and classical subtypes in advanced
pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate …

Prognostically relevant RNA expression states exist in pancreatic ductal adenocarcinoma
(PDAC), but our understanding of their drivers, stability, and relationship to therapeutic …

Pancreatic ductal adenocarcinoma (PDA) is characterized by aggressive local invasion and
metastatic spread, leading to high lethality. Although driver gene mutations during PDA …